| Name | Title | Contact Details |
|---|
Zitomer Pharmacy Inc is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our Focus Neauvia North America was established in 2012 and is headquartered in Raleigh, North Carolina. It is the U.S. subsidiary of Neauvia, a global aesthetics brand present in more than 50 countries. Neauvia’s global headquarters is located in Luga...
Kamada is focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company`s flagship product is GLASSIA®, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets GLASSIA® in the U.S. through a strategic partnership with Baxalta (now part of Shire plc) and in other counties through local distributors. In addition to GLASSIA®, Kamada has a product line of six other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada`s rabies immune globulin (Human) product received FDA approval for Post-Exposure Prophylaxis against rabies infection and is marketed in the U.S. through a partnership with Kedrion Biopharma. Kamada has late-stage products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency and, in addition, its intravenous AAT is in development for other indications, such as type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 complementary products in Israel that are manufactured by third parties.
At Patheon, we deliver enhanced simplicity, speed, and quality to clients across the pharmaceutical and biotechnology sectors. As a leading global provider of pharmaceutical development and manufacturing services, we provide a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. With a reputation for scientific and technical excellence, combined with a passion for delivering quality products on time, every time, our approximately 8,700 employees across North America, Europe, Latin America and Australia have enabled Patheon to achieve industry-leading growth. When you join Patheon, you are joining a team that is dedicated to transforming an industry and advancing our clients’ successes, today and tomorrow. Every day, our teams seek out opportunities for operational improvements across the enterprise to ensure we can deliver medicines that are right the first time and on time, while continually working to simplify the supply chain process and focus on what’s next by optimizing our offerings in innovative ways.
Norbrook® is a true innovator and dedicated to novel research and revolutionary processes and products. Lord Ballyedmond, Founder, Chairman and CEO of the Norbrook Group began his career in the pharmaceutical industry in the USA in the 1960s and now controls the largest privately owned pharmaceutical company in the world. The company is very active in both medical and veterinary products. Research and Development is the key to Norbrook`s success with the R&D Department central to the company`s structure. It is responsible for new product development, technical support and meeting regulatory and licensing protocols. Norbrook invests more than 10% of its turnover annually in research and development of new products. The company is at the forefront of formulation technology and has developed many new chemical routes for the synthesis of active materials. Norbrook has formulated and registered more than 800 products in 120 countries. The on-going success of the company is conditional on the expertise, knowledge and innovation of the staff employed. Norbrook prides itself on attracting the highest calibre of individual to the company and boasts a multi-national workforce committed to constantly pushing the boundaries and challenging technologies to ensure that Norbrook remains the leading force in pharmaceuticals that it is today.